P2Y_(12)受体及其抑制剂与急性冠脉综合征  

Research progress of P2Y_(12) receptor and its inhibitors in acute coronary syndrome

作　　者：李颖[1,2] 宋淑亮[1,2] 梁浩[1,2] 吉爱国[1,2,3] 

机构地区：[1]山东大学海洋学院,威海264209 [2]山东大学威海国际生物技术研发中心,威海264209 [3]山东大学药学院,济南250012

出　　处：《生命的化学》2016年第5期639-644,共6页Chemistry of Life

基　　金：山东省自然科学基金项目(ZR2015PH050)

摘　　要：急性冠脉综合征(acute coronary syndrome,ACS)是指冠状动脉粥样硬化斑块破裂或侵袭,继发完全或不完全闭塞性血栓所导致的心脏急性缺血综合征。P2Y_(12)受体属于视紫红质类G蛋白偶联受体家族,主要分布于血小板表面,是一种跨膜糖蛋白,当该受体与其配体结合后,使血小板聚集、活化,导致血栓形成。该受体在其他多种细胞中也有分布,与人体的炎症和免疫相关。目前,以P2Y_(12)受体抑制剂为代表的抗血小板药物是急性冠脉综合征的主要研究领域。本文主要对P2Y_(12)受体的结构特征、生理功能及其抑制剂的主要种类和临床应用进行综述。Acute coronary syndrome（ACS） is a kind of acute cardiac ischemia syndrome which is always associated with rupture of atherosclerotic plaques and partial or complete thrombosis of the infarct-related artery. P2Y_（12） receptor is a transmembrane glycoprotein which belongs to rhodopsin-like G protein coupled receptor family, mainly distributes in the surface of platelets. After the receptor binds to its ligands, platelets are aggregated and then activated, resulting in the formation of thrombosis. P2Y_（12） receptor also distributes in other cells which are related to inflammation and immunity. At present, the research of ACS focuses on antiplatelet drugs represented by P2Y_（12） receptor inhibitors. This review summarizes the structural characteristic, physiological function of P2Y_（12） receptor and clinical application of its inhibitors.

关 键 词：急性冠脉综合征 血小板 P2Y_(12)受体抑制剂 炎症 免疫 

分 类 号：R541.4[医药卫生—心血管疾病]